3651 results for «211»
3651 results
TAVI complications: impact and improvement
20 May 2026 – From EuroPCR 2026
This session examines critical complications associated with TAVI and strategies to mitigate their impact. Topics include carbon-dioxide flushing to reduce brain injury, management of cardiac tamponade, AI-driven customization of TAVI in complex anatomies, and the influence of vascular complications on post-procedural quality of life.
INOCA/ANOCA: technical aspects
20 May 2026 – From EuroPCR 2026
This session covers technical aspects critical to the evaluation and management of ischemia with non-obstructive coronary arteries (INOCA) and angina with non-obstructive coronary arteries (ANOCA). Key topics include the impact of guide catheter shape, injection techniques for thermodilution measurements, advanced perfusion CMR diagnostics, and the physiological...
Continual refinement in LAA closure
20 May 2026 – From EuroPCR 2026
This session presents the latest advancements in left atrial appendage closure (LAAC). It covers new risk scoring systems, sex-specific outcome analyses, safety in elderly populations, and comparative data between LAMBRE and WATCHMAN devices from a high-volume center, highlighting continual refinement in LAAC strategies.
New frontiers in coronary disease treatment
21 May 2026 – From EuroPCR 2026
Examine recent advances in coronary disease treatment focusing on drug-eluting stents versus drug-coated balloon strategies. This session presents real-world data on lesion preparation, sex-specific outcomes, physiological disease patterns, and procedural factors influencing PCI success.
Strategies to enhance bifurcation PCI outcomes
21 May 2026 – From EuroPCR 2026
This session addresses strategies to optimize outcomes in coronary bifurcation PCI. It evaluates the impact of cutting and scoring balloons versus non-compliant balloons on stent expansion, predictors of target vessel revascularization using the POKI technique, and compares stent and non-stent approaches in side branch myocardial infarction...
Aortic stenosis: from diagnostic to treatment
21 May 2026 – From EuroPCR 2026
This session provides an in-depth review of contemporary management of aortic stenosis, covering diagnostic advancements, temporal trends, and treatment outcomes. It includes insights from the LAPLACE-TAVI registry focusing on low-risk patients, discusses the growing feasibility of day-case TAVI procedures, compares transcatheter and surgical valve replacements in...
Left main PCI, what is known and what is new
21 May 2026 – From EuroPCR 2026
This session examines both established knowledge and novel advances in left main PCI. Topics include the use of novel stents and laser atherectomy in calcified lesions, the prognostic impact of cardiac motion during bifurcation PCI, effects of left ventricular dysfunction, and sex-specific survival outcomes, as well...
STEMI management around the world
21 May 2026 – From EuroPCR 2026
This session presents a global perspective on STEMI management, addressing strategies to reduce reperfusion delays through nurse-integrated pathways and comparing intracoronary versus intravenous Tirofiban use during primary PCI. It includes epidemiological insights from Rwanda and Egypt, evaluates thrombo-aspiration practices in Sub-Saharan Africa, and examines outcomes in...
PCR STATEMENT on the 2-year clinical outcomes from the Evolut low risk trial
18 May 2021
Transcatheter aortic valve implantation (TAVI) offers an effective, less invasive therapeutic alternative to surgical aortic valve replacement in patients with symptomatic, severe aortic stenosis. Although TAVI is demonstrated to be superior to medical therapy or surgery in patients who are at prohibitive or high risk for...
INFINITY-SWEDEHEART - Percutaneous coronary intervention with a bioadaptor compared to a contemporary drug eluting stent- one year primary outcomes
03 Sep 2024
Daniele Giacoppo provides his take on the main results of the INFINITY-SWEDEHEART trial presented by David Erlinge at the ESC Congress 2024 in London.
Author
BioCardia reports positive interim results from phase III CardiAMP cell therapy heart failure trial, with compelling data in subgroup with elevated NTproBNP biomarker for heart failure.
04 Mar 2024